Email this article Modern methods of treatment of anaplastic thyroid cancer (clinical case)
- Authors: Romanov I.S.1,2, Bokhyan V.Y.1,2, Ignatova A.V.1, Pershina Y.F.3, Vorobyov S.L.4, Puzenko D.V.1,5, Stroganova A.M.1, Martynova O.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
- LLC “National Center for Clinical Morphological Diagnostics”
- City Clinical Hospital No. 1, Moscow Healthcare Department
- Issue: Vol 16, No 2 (2026)
- Pages: 99-108
- Section: CLINICAL CASE
- Published: 18.09.2026
- URL: https://ogsh.abvpress.ru/jour/article/view/1151
- DOI: https://doi.org/10.17650/2222-1468-2026-16-2-99-108
- ID: 1151
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
The article presents a clinical case of treating stage IV anaplastic thyroid cancer with a V600E mutation in the BRAF gene and distant metastasis (including metastases to the right ventricle of the heart and the right adrenal gland). At the first stage, targeted therapy (dabrafenib + trametinib) was performed, which allowed achieving pronounced clinico-metabolic regression and performing radical multi-stage surgical treatment. Subsequently, with the development of drug resistance and the detection of high expression of programmed cell death 1 ligand (PD-L1) (Combined Positive Score (CPS) – the ratio of the number of PD-L1-positive cells to the total number of tumor cells = 100), immunotargeted therapy with pembrolizumab in combination with lenvatinib was prescribed, resulting in a partial metabolic response. Despite the subsequent disease progression, overall survival from the time of diagnosis was 46 months. The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.
About the authors
I. S. Romanov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: pershinajulia15@yandex.ru
ORCID iD: 0000-0002-5421-5985
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522; 1 Ostrovityanova St., Moscow 117513
V. Yu. Bokhyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: pershinajulia15@yandex.ru
ORCID iD: 0000-0002-9066-5190
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522; 1 Ostrovityanova St., Moscow 117513
A. V. Ignatova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: pershinajulia15@yandex.ru
ORCID iD: 0000-0002-6796-0968
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522
Yulia F. Pershina
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Author for correspondence.
Email: pershinajulia15@yandex.ru
ORCID iD: 0009-0004-3852-5985
Russian Federation, Bld. 1, 2 / 1 Barricadnaya St., 123995 Moscow
S. L. Vorobyov
LLC “National Center for Clinical Morphological Diagnostics”
Email: pershinajulia15@yandex.ru
ORCID iD: 0000-0002-7817-9069
Russian Federation, 32 Slavy Prospekt, Saint Petersburg 192071
D. V. Puzenko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; City Clinical Hospital No. 1, Moscow Healthcare Department
Email: pershinajulia15@yandex.ru
ORCID iD: 0000-0002-2607-3895
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522; 8 Leninsky Prospekt, Moscow 117049
A. M. Stroganova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: pershinajulia15@yandex.ru
ORCID iD: 0000-0002-7297-5240
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522
O. A. Martynova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: pershinajulia15@yandex.ru
ORCID iD: 0009-0005-7617-225X
Russian Federation, 24 Kashirskoe Shosse, Moscow 115522
References
- The state of oncological care for the Russian population in 2024. Eds.: A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2025. 275 p. (In Russ.).
- Ho A.S., Luu M., Barrios L. et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. JAMA Oncol 2020;6(5):706–13. doi: 10.1001/jamaoncol.2019.6851
- Iñiguez-Ariza N.M., Ryder M.M., Hilger C.R., Bible K.C. Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer. Thyroid 2017;27(7):923–7. doi: 10.1089/thy.2016.0627
- Wendler J., Kroiss M., Gast K. et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol 2016;175(6):521–9. doi: 10.1530/EJE-16-0574
- Guerra A., Di Crescenzo V., Garzi A. et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg 2013;13(Suppl 2):S44. doi: 10.1186/1471-2482-13-S2-S44
- NCCN Clinical Practice Guidelines in Oncology: thyroid carcinoma. Available at: https://arupconsult.com/reference/nccn-thyroid-carcinoma-v52024
- Subbiah V., Kreitman R.J., Wainberg Z.A. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 2022;33(4):406–15. doi: 10.1016/j.annonc.2021.12.014
- Dierks C., Ruf J., Seufert J. et al. Phase II ATLEP trial: final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol 2022;33(Suppl S7): S750–7. doi: 10.1016/j.annonc.2022.07.1726
- Pylev A.L., Romanov D.S., Lasunin N.V. et al. Anaplastic thyroid cancer: current capabilities of an oncologist. Opukholi golovy i shei = Head and Neck Tumors 2023;13(1):116–25. (In Russ.). doi: 10.17650/2222-1468-2023-13-1-116-125
Supplementary files
